Trial
NCT03344419
Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders
Phase IIISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
New York State Psychiatric Institute
Collaborators
National Institute on Drug Abuse (NIDA)
Condition
Cocaine Use Disorder
Intervention
CI-581a
Why stopped
Funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-16